CO4920219A1 - Metodos y composiciones para estimular el crecimiento de neuritas - Google Patents
Metodos y composiciones para estimular el crecimiento de neuritasInfo
- Publication number
- CO4920219A1 CO4920219A1 CO97066754A CO97066754A CO4920219A1 CO 4920219 A1 CO4920219 A1 CO 4920219A1 CO 97066754 A CO97066754 A CO 97066754A CO 97066754 A CO97066754 A CO 97066754A CO 4920219 A1 CO4920219 A1 CO 4920219A1
- Authority
- CO
- Colombia
- Prior art keywords
- branched
- alkyl
- hydrogen
- straight
- isoquinolinyl
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 210000002241 neurite Anatomy 0.000 title 1
- -1 pyraxolyl Chemical group 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 abstract 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 abstract 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 abstract 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 abstract 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000005955 1H-indazolyl group Chemical group 0.000 abstract 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 abstract 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 abstract 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 abstract 1
- 125000003828 azulenyl group Chemical group 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 abstract 1
- 150000003857 carboxamides Chemical class 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 abstract 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 230000002276 neurotropic effect Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 abstract 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 abstract 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/748,448 US5811434A (en) | 1996-11-13 | 1996-11-13 | Methods and compositions for stimulating neurite growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4920219A1 true CO4920219A1 (es) | 2000-05-29 |
Family
ID=25009490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO97066754A CO4920219A1 (es) | 1996-11-13 | 1997-11-13 | Metodos y composiciones para estimular el crecimiento de neuritas |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5811434A (forum.php) |
| EP (1) | EP0941112B1 (forum.php) |
| JP (1) | JP2001503777A (forum.php) |
| KR (1) | KR20000068963A (forum.php) |
| CN (1) | CN1239435A (forum.php) |
| AR (1) | AR013873A1 (forum.php) |
| AT (1) | ATE232395T1 (forum.php) |
| AU (1) | AU5439698A (forum.php) |
| BR (1) | BR9712947A (forum.php) |
| CA (1) | CA2270629A1 (forum.php) |
| CO (1) | CO4920219A1 (forum.php) |
| DE (1) | DE69719063T2 (forum.php) |
| DK (1) | DK0941112T3 (forum.php) |
| EA (1) | EA199900462A1 (forum.php) |
| ES (1) | ES2187832T3 (forum.php) |
| IL (1) | IL129556A0 (forum.php) |
| IN (1) | IN183279B (forum.php) |
| NZ (1) | NZ335395A (forum.php) |
| PL (1) | PL333242A1 (forum.php) |
| WO (1) | WO1998020892A1 (forum.php) |
| ZA (1) | ZA9710258B (forum.php) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6133456A (en) * | 1994-08-18 | 2000-10-17 | Ariad Gene Therapeutics, Inc. | Synthetic multimerizing agents |
| US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
| US6150527A (en) * | 1994-08-18 | 2000-11-21 | Ariad Pharmaceuticals, Inc. | Synthetic multimerizing agents |
| US5859031A (en) | 1995-06-07 | 1999-01-12 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
| US5840736A (en) * | 1996-11-13 | 1998-11-24 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
| US5780484A (en) * | 1996-11-13 | 1998-07-14 | Vertex Pharmaceuticals Incorporated | Methods for stimulating neurite growth with piperidine compounds |
| US6242468B1 (en) | 1997-02-27 | 2001-06-05 | Jia-He Li | Carbamate and urea compositions and neurotrophic uses |
| US6514686B2 (en) | 1997-04-28 | 2003-02-04 | The University Of British Columbia | Method and composition for modulating amyloidosis |
| US20010049381A1 (en) | 1997-06-04 | 2001-12-06 | Gpl Nil Holdings, Inc., | Pyrrolidine derivative hair growth compositions and uses |
| US5945441A (en) | 1997-06-04 | 1999-08-31 | Gpi Nil Holdings, Inc. | Pyrrolidine carboxylate hair revitalizing agents |
| US6852496B1 (en) | 1997-08-12 | 2005-02-08 | Oregon Health And Science University | Methods of screening for agents that promote nerve cell growth |
| US5968921A (en) * | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
| AU1708099A (en) | 1998-06-03 | 1999-12-20 | Amgen, Inc. | N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres |
| US6331537B1 (en) | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
| CN1318067A (zh) | 1998-07-17 | 2001-10-17 | 阿古龙制药有限公司 | 用于刺激神经元生长和延伸的化合物、组合物和方法 |
| GB9815880D0 (en) | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| US6399648B1 (en) * | 1998-08-14 | 2002-06-04 | Gpi Nil Holdings, Inc. | N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders |
| US6218423B1 (en) | 1998-08-14 | 2001-04-17 | Gpi Nil Holdings, Inc. | Pyrrolidine derivatives for vision and memory disorders |
| US7338976B1 (en) | 1998-08-14 | 2008-03-04 | Gpi Nil Holdings, Inc. | Heterocyclic esters or amides for vision and memory disorders |
| US6395758B1 (en) | 1998-08-14 | 2002-05-28 | Gpi Nil Holdings, Inc. | Small molecule carbamates or ureas for vision and memory disorders |
| US6462072B1 (en) | 1998-09-21 | 2002-10-08 | Gpi Nil Holdings, Inc. | Cyclic ester or amide derivatives |
| US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
| US6300341B1 (en) | 1998-09-30 | 2001-10-09 | The Procter & Gamble Co. | 2-substituted heterocyclic sulfonamides |
| US6228872B1 (en) | 1998-11-12 | 2001-05-08 | Bristol-Myers Squibb Company | Neurotrophic diamide and carbamate agents |
| WO2001002368A1 (en) * | 1999-07-06 | 2001-01-11 | Vertex Pharmaceuticals Incorporated | N-heterocyclic derivatives with neuronal activity |
| US6734211B1 (en) | 1999-07-09 | 2004-05-11 | Oregon Health & Sciences University | Compositions and methods for promoting nerve regeneration |
| US6323215B1 (en) * | 1999-07-09 | 2001-11-27 | Ortho-Mcneil Pharmaceutical, Inc. | Neurotrophic tetrahydroisoquinolines and tetrahydrothienopyridines, and related compositions and methods |
| WO2001017953A1 (en) | 1999-09-08 | 2001-03-15 | Guilford Pharmaceuticals Inc. | Non-peptidic cyclophilin binding compounds and their use |
| US6417189B1 (en) | 1999-11-12 | 2002-07-09 | Gpi Nil Holdings, Inc. | AZA compounds, pharmaceutical compositions and methods of use |
| US7253169B2 (en) | 1999-11-12 | 2007-08-07 | Gliamed, Inc. | Aza compounds, pharmaceutical compositions and methods of use |
| BR0015486A (pt) * | 1999-11-12 | 2002-07-02 | Alcon Inc | Ligandos de neurofilina para tratamento de condições oculares |
| US6818643B1 (en) | 1999-12-08 | 2004-11-16 | Bristol-Myers Squibb Company | Neurotrophic bicyclic diamides |
| WO2001046195A1 (en) | 1999-12-21 | 2001-06-28 | Gpi Nil Holdings, Inc. | Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same |
| NZ520638A (en) * | 2000-02-11 | 2004-05-28 | Vertex Pharma | Piperazine and piperidine derivatives |
| US6693099B2 (en) | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
| US6376514B1 (en) * | 2000-10-17 | 2002-04-23 | The Procter & Gamble Co. | Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof |
| EP1360173A2 (en) | 2001-01-25 | 2003-11-12 | Guilford Pharmaceuticals Inc. | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| JP2005500270A (ja) * | 2001-05-29 | 2005-01-06 | ギルフォード ファーマシュウティカルズ インコーポレイテッド | 手術の結果として発生した神経損傷を治療するための方法 |
| WO2003062773A1 (en) * | 2002-01-24 | 2003-07-31 | Pei Electronics, Inc. | Compact integrated infrared scene projector |
| KR20040011237A (ko) * | 2002-07-29 | 2004-02-05 | 김윤희 | Ｐｄｇｆ, 그의 유도체 및 약학적으로 허용되는 그의 염을함유하는 신경세포 보호 및 재생용 조성물 |
| US20040034019A1 (en) * | 2002-08-08 | 2004-02-19 | Ronald Tomlinson | Piperazine and piperidine derivatives |
| KR20050047132A (ko) * | 2002-10-03 | 2005-05-19 | 버텍스 파마슈티칼스 인코포레이티드 | 신경계 질환 치료용 피페라진 및 피페리딘 유도체 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192773A (en) * | 1990-07-02 | 1993-03-09 | Vertex Pharmaceuticals, Inc. | Immunosuppressive compounds |
| US5543423A (en) * | 1994-11-16 | 1996-08-06 | Vertex Pharmaceuticals, Incorporated | Amino acid derivatives with improved multi-drug resistance activity |
| IL115685A (en) * | 1994-11-16 | 2000-08-31 | Vertex Pharma | Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof |
| US5726184A (en) * | 1995-05-19 | 1998-03-10 | Vertex Pharmaceuticals Incorporated | Tetralin compounds with improved MDR activity |
| US5859031A (en) * | 1995-06-07 | 1999-01-12 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
| US5614547A (en) * | 1995-06-07 | 1997-03-25 | Guilford Pharmaceuticals Inc. | Small molecule inhibitors of rotamase enzyme |
| US5696135A (en) * | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
| US6037370A (en) * | 1995-06-08 | 2000-03-14 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
| US5801197A (en) * | 1995-10-31 | 1998-09-01 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
-
1996
- 1996-11-13 US US08/748,448 patent/US5811434A/en not_active Expired - Lifetime
-
1997
- 1997-11-13 CA CA002270629A patent/CA2270629A1/en not_active Abandoned
- 1997-11-13 ZA ZA9710258A patent/ZA9710258B/xx unknown
- 1997-11-13 DK DK97948308T patent/DK0941112T3/da active
- 1997-11-13 IN IN2150CA1997 patent/IN183279B/en unknown
- 1997-11-13 IL IL12955697A patent/IL129556A0/xx unknown
- 1997-11-13 AT AT97948308T patent/ATE232395T1/de not_active IP Right Cessation
- 1997-11-13 NZ NZ335395A patent/NZ335395A/xx unknown
- 1997-11-13 EA EA199900462A patent/EA199900462A1/ru unknown
- 1997-11-13 CN CN97180249A patent/CN1239435A/zh active Pending
- 1997-11-13 AR ARP970105319A patent/AR013873A1/es unknown
- 1997-11-13 PL PL97333242A patent/PL333242A1/xx unknown
- 1997-11-13 DE DE69719063T patent/DE69719063T2/de not_active Expired - Lifetime
- 1997-11-13 BR BR9712947-0A patent/BR9712947A/pt not_active Application Discontinuation
- 1997-11-13 KR KR1019997004193A patent/KR20000068963A/ko not_active Withdrawn
- 1997-11-13 EP EP97948308A patent/EP0941112B1/en not_active Expired - Lifetime
- 1997-11-13 CO CO97066754A patent/CO4920219A1/es unknown
- 1997-11-13 WO PCT/US1997/020867 patent/WO1998020892A1/en not_active Ceased
- 1997-11-13 AU AU54396/98A patent/AU5439698A/en not_active Abandoned
- 1997-11-13 ES ES97948308T patent/ES2187832T3/es not_active Expired - Lifetime
- 1997-11-13 JP JP52286698A patent/JP2001503777A/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| BR9712947A (pt) | 2000-03-28 |
| IL129556A0 (en) | 2000-02-29 |
| US5811434A (en) | 1998-09-22 |
| CN1239435A (zh) | 1999-12-22 |
| JP2001503777A (ja) | 2001-03-21 |
| ZA9710258B (en) | 1998-05-28 |
| EP0941112A1 (en) | 1999-09-15 |
| AU5439698A (en) | 1998-06-03 |
| ES2187832T3 (es) | 2003-06-16 |
| IN183279B (forum.php) | 1999-10-30 |
| AR013873A1 (es) | 2001-01-31 |
| DE69719063D1 (de) | 2003-03-20 |
| KR20000068963A (ko) | 2000-11-25 |
| DK0941112T3 (da) | 2003-05-19 |
| EA199900462A1 (ru) | 2000-02-28 |
| DE69719063T2 (de) | 2003-07-31 |
| CA2270629A1 (en) | 1998-05-22 |
| PL333242A1 (en) | 1999-11-22 |
| WO1998020892A1 (en) | 1998-05-22 |
| NZ335395A (en) | 1999-07-29 |
| ATE232395T1 (de) | 2003-02-15 |
| EP0941112B1 (en) | 2003-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4920219A1 (es) | Metodos y composiciones para estimular el crecimiento de neuritas | |
| CO4930260A1 (es) | Metodos y composiciones para estimular el crecimiento de neuritas | |
| CO5080733A1 (es) | Metodos y composiciones para estimular el crecimiento de neuritas | |
| CO5080732A1 (es) | Compuestos que poseen actividad neuronal | |
| AR020055A1 (es) | Una composicion farmaceutica o cosmetica que contiene una sustancia de esmalte activa, usos de dicha composicion y un metodo para preparar la misma. | |
| NO971862L (no) | Nye inhibitorer av metalloprotease, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem | |
| NO20013254L (no) | Nye difenylureaforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske samensetninger som inneholder dem | |
| ATE204748T1 (de) | Neue pharmazeutische pelletformulierung | |
| NO20014102L (no) | Nye tricykliske forbindelser og deres anvendelse innenfor medisin, fremgangsmåte for deres fremstilling og farmasöytisksammensetning som inneholder dem | |
| BR9803883A (pt) | Derivado de amida. | |
| ES2172744T3 (es) | Composiciones farmaceuticas que comprenden mirtazapina y uno o varios inhibidores selectivos de asimilacion de serotonina. | |
| UY24436A1 (es) | Formulaciones orales de paroxetina de liberación controlada y retardada | |
| ATE220918T1 (de) | Matrixprotein enthaltende zusammensetzungen zur wundheilung | |
| ATE473749T1 (de) | Verwendung von rhamnolipiden zur wundheilung, behandlung und vorbeugung einer zahnfleischerkrankung und periodontaler regeneration | |
| NO974693D0 (no) | Farmasöytisk preparat inneholdende N-klorfenyl-karbamater, N-klorfenyltiokarbamater og N-fosfonoglycin-derivater for å inhibere vekst av cancer og virus i pattedyr | |
| NO970610L (no) | Sammensetning for selektiv frigjöring av en aktiv ingrediens | |
| Alsareii et al. | Topical application of Premna integrifolia Linn on skin wound injury in rats accelerates the wound healing process: Evidence from in vitro and in vivo experimental models | |
| NO20031808D0 (no) | Oralt preparat som inneholder sjövekster for reduksjon av plakk og calculus | |
| NO20012428D0 (no) | Substituerte kaprolaktamer, farmasöytiske sammensetninger som inneholder dem og deres anvendelse ved behandling av tumorer | |
| ES2238734T3 (es) | Barrera contra la formacion de placa dental. | |
| DE3875349D1 (de) | Glykosaminoglykan zur behandlung von diabetischer mikroangiopathie. | |
| BR0316382A (pt) | Método de tratamento de enfarte do miocárdio e artigos de manufatura contendo um inibidor quìmico de quìnase de tirosina da famìlia src para tal tratamento | |
| ATE555787T1 (de) | Behandlungseffekte von überschüssigen reaktiven sauerstoffspezies | |
| Pimentel et al. | Enamel matrix derivative versus guided tissue regeneration in the presence of nicotine: a histomorphometric study in dogs | |
| DE60126591D1 (de) | In-vitro-Verwendung von Astaxanthin zur Vorbehandlung von Zellen vor UV-Bestrahlung zwecks Hemmung der Aktivierung von NF-KB |